Cohance Lifesciences LimitedCOHANCECorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 13 quarters of data

₹464.05

MCap ₹17,754 Cr · P/E 100.0

Cohance Lifesciences Limited — Stock analysis & AI research Cohance Lifesciences Limited — Seasonality — best & worst months Cohance Lifesciences Limited — Technical indicators & charts Cohance Lifesciences Limited — Technical setup — score, trend, support & resistance Cohance Lifesciences Limited — Live exchange announcements

📋 Small Cap Stocks List 📈 MACD Bullish Crossover 📈 Bollinger Squeeze Stocks 📈 Stocks Above Anchored VWAP ⚖️ vs Acutaas Chemicals ⚖️ vs Rubicon Research 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹360 Cr

Sales · Jun 2026

-25.6% YoY

₹26 Cr

Operating Profit · Jun 2026

-74.6% YoY

7.4%

OPM % · Jun 2026

-65.6% YoY

₹1 Cr

Net Profit · Jun 2026

-97.3% YoY

₹0.04

EPS · Jun 2026

-97.1% YoY

📝 Cohance Lifesciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Cohance Lifesciences Limited reported revenue of ₹360 crore for the quarter ended June 2026 (Q1 FY27), down 25.6% from ₹484 crore in the same quarter last year, and down 36.6% sequentially over the March 2026 quarter.

Net profit fell 97.3% year-on-year to ₹1 crore, from ₹53 crore. Earnings per share (EPS) came in at ₹0.04.

Operating profit stood at ₹26 crore — an operating margin (OPM) of 7.4%, compared with 21.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Cohance Lifesciences Limited posted revenue of ₹2,030 crore, with a net profit of ₹229 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,907 crore with a net profit of ₹178 crore.

Valuation snapshot

At the current price of ₹464.05, COHANCE has a market capitalisation of ₹17,754 crore and a trailing P/E of about 100.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 57.48%, foreign institutional investors (FIIs) 7.71%, domestic institutional investors (DIIs) 18.86%, public shareholders 15.95% of Cohance Lifesciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹17,754 Cr

Current Price ?

₹464.1

P/E ?

100.00above ind

Industry P/E ?

35.00

P/B ?

N/A

P/S ?

9.31

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.0%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹1,907 Cr

OPM ?

19.8%

Profit after tax (TTM) ?

₹178 Cr

EPS (TTM) ?

₹4.64

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹360 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

-25.6%

YoY qtr profit growth ?

-97.3%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

14.3

Current Ratio ?

N/A

Ownership

Promoter holding ?

57.48%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

5.0%

Return 6 months ?

18.8%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	348	364	344	225	213	244	275	330	484	498	482	568	360	-25.6%	-36.6%
Operating Profit	147	175	170	97	68	72	115	67	104	131	103	117	26	-74.6%	-77.3%
Other Income	13	11	10	14	14	17	15	7	13	26	6	-17	12	-7.2%	+170.3%
Interest	1	2	1	1	1	2	3	2	7	5	5	5	2	-68.8%	-59.0%
Depreciation	11	11	11	10	11	16	13	15	31	31	33	38	34	+9.4%	-8.9%
Profit Before Tax	147	172	168	101	70	71	115	56	71	121	65	56	2	-96.9%	-96.1%
Net Profit	109	130	124	75	52	53	86	44	53	94	47	35	1	-97.3%	-95.9%
EPS	4.30	5.11	4.88	2.94	2.06	2.10	3.39	1.74	1.38	2.46	1.24	0.90	0.04	-97.1%	-95.6%
OPM %	42.2%	47.9%	49.4%	43.3%	32.0%	29.6%	41.9%	20.3%	21.5%	26.3%	21.3%	20.5%	7.4%	-65.6%	-63.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹2,030 Cr	₹1,907 Cr	—
Operating Profit	—	₹454 Cr	₹377 Cr	—
OPM %	—	22.38%	19.76%	—
NPM %	—	11.26%	9.31%	—
Other Income	—	₹28 Cr	₹27 Cr	—
Depreciation	—	₹134 Cr	₹137 Cr	—
Interest	—	₹22 Cr	₹18 Cr	—
EBIT	—	₹321 Cr	₹240 Cr	—
PBT	—	₹314 Cr	₹245 Cr	—
Tax	—	₹63 Cr	₹45 Cr	—
Net Profit	—	₹229 Cr	₹178 Cr	—
EPS	—	₹5.98	₹4.64	—
Material Cost	—	₹557 Cr	₹533 Cr	—
Employee Cost	—	₹284 Cr	₹277 Cr	—
Extraordinary Items	—	₹3 Cr	₹-5 Cr	—

👥 Shareholding (latest 1 periods)

Metric	Sep 2026	% Chg
Promoters	57.48%	—
FIIs	7.71%	—
DIIs	18.86%	—
Public	15.95%	—
No. of Shareholders	93,846	—

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUNPHARMA Sun Pharmaceutical	₹1,840.00	441,478	36.5	59,911	12,104	29.8%	20.2%	11.2%	5.1%	10.5%	27.0%
2	DIVISLAB Divi's Laboratories	₹9,235.00	245,160	83.8	11,230	2,925	35.3%	26.0%	12.8%	16.7%	27.8%	65.5%
3	TORNTPHARM Torrent Pharmaceuticals	₹4,931.00	187,559	87.1	15,723	2,156	33.0%	13.7%	21.4%	11.9%	54.8%	3.3%
4	ZYDUSLIFE Zydus Lifesciences	₹1,162.20	115,930	23.2	27,148	5,070	31.2%	18.7%	16.8%	12.0%	16.2%	14.5%
5	CIPLA Cipla	₹1,366.00	110,353	32.7	28,324	3,356	18.7%	11.8%	2.2%	-26.7%	2.3%	-39.2%
6	LAURUSLABS Laurus Labs	₹1,969.00	106,387	97.2	7,270	1,090	28.0%	15.0%	22.7%	147.9%	29.1%	123.9%
7	DRREDDY Dr. Reddy's	₹1,165.50	97,085	29.3	28,704	3,273	15.3%	11.4%	-10.4%	-25.8%	-5.6%	-69.2%
8	AUROPHARMA Aurobindo Pharma	₹1,679.80	96,652	26.2	34,935	3,711	20.3%	10.6%	6.1%	0.6%	16.3%	25.2%
9	LUPIN Lupin	₹2,095.00	95,797	17.9	27,958	5,356	31.5%	19.2%	23.1%	62.0%	31.9%	87.8%
10	MANKIND Mankind Pharma	₹2,280.00	94,174	46.1	14,738	2,067	26.0%	14.0%	16.3%	-3.7%	12.9%	29.1%
11	GLENMARK Glenmark Pharmaceuticals	₹2,419.20	68,276	38.0	17,737	1,797	27.0%	10.1%	-61.2%	-67.4%	23.1%	927.9%
12	ALKEM Alkem Laboratories	₹5,243.50	62,694	29.1	15,081	2,187	20.1%	14.5%	13.5%	7.6%	10.9%	-21.6%
13	ABBOTINDIA Abbott India	₹25,860.00	54,951	34.0	7,005	1,615	28.1%	23.1%	8.1%	9.7%	4.4%	17.2%
14	IPCALAB Ipca Laboratories	₹1,964.20	49,833	38.0	10,125	1,379	22.0%	13.6%	7.9%	55.0%	20.8%	82.2%
15	GLAND Gland Pharma	₹2,935.90	48,433	47.1	6,431	1,028	25.3%	16.0%	-64.7%	-48.4%	22.3%	96.7%
16	AJANTPHARM Ajanta Pharma	₹3,398.90	42,472	37.4	5,777	1,135	25.4%	19.7%	17.3%	14.8%	24.8%	30.9%
17	JBCHEPHARM J. B.	₹2,416.10	38,793	53.4	4,148	709	26.7%	17.1%	5.9%	7.5%	-4.8%	-30.7%
18	EMCURE EMCURE PHARMACEUTICALS	₹1,975.10	37,470	37.0	9,684	1,019	20.4%	10.5%	16.6%	33.1%	22.8%	36.0%
19	WOCKPHARMA Wockhardt	₹2,021.50	32,848	92.5	3,133	353	19.9%	11.3%	-2.3%	342.1%	25.9%	199.1%
20	NEULANDLAB Neuland Laboratories	₹23,455.00	30,093	82.7	2,023	365	28.4%	18.0%	37.0%	40.2%	136.3%	666.0%
21	PPLPHARMA Piramal Pharma	₹211.50	28,024	113.5	9,206	247	11.0%	2.7%	-3.1%	-37.9%	17.4%	-161.3%
22	GRANULES Granules India	₹885.60	21,945	32.8	5,633	663	22.7%	11.8%	19.7%	18.8%	22.0%	59.3%
23	CAPLIPOINT Caplin Point	₹2,752.60	20,923	31.4	2,287	678	34.8%	29.7%	12.9%	20.2%	19.6%	18.8%
24	ERIS Eris Lifesciences	₹1,358.00	18,820	29.0	3,230	666	35.2%	20.6%	8.2%	72.6%	13.0%	14.6%
25	COHANCE COHANCE LIFESCIENCES	₹439.55	16,817	n/m	2,141	58	14.8%	2.7%	141.4%	-18.1%	-23.1%	-197.4%

❓ Frequently asked questions

What was Cohance Lifesciences Limited's revenue in Q1 FY27?

What was Cohance Lifesciences Limited's net profit in Q1 FY27?